209394-46-7

Basic information

• Product Name: Ladostigil tartrate
• Synonyms: ethylmethyl-carbamic acid (3r)-2,3-dihydro-3-(2-propynylamino)-1h-inden-5-yl ester (2r,3r)-2,3-dihydroxybutanedioate (2:1);ladostigil tartrate;Tv 3326;Unii-2J1346C51h;N-Ethyl-N-MethylcarbaMic Acid (3R)-2,3-Dihydro-3-(2-propyn-1-ylaMino)-1H-inden- 5-yl Ester (2R,3R)-2,3-Dihydroxybutanedioate;Burixafor
• CAS NO: 209394-46-7
• Molecular Formula: 0C₄H₆O₆*C₁₆H₂₀N₂O₂
• Molecular Weight: 694.777
• Product Categories: Amines;Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 209394-46-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 412.4 °C at 760 mmHg
• Flash Point: 203.2 °C
• Appearance: /
• Vapor Pressure: 5.19E-07mmHg at 25°C
• CAS DataBase Reference: Ladostigil tartrate(CAS DataBase Reference)
• NIST Chemistry Reference: Ladostigil tartrate(209394-46-7)
• EPA Substance Registry System: Ladostigil tartrate(209394-46-7)

Safety Data

• Hazardous Substances Data: 209394-46-7(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 209394-46-7 differently. You can refer to the following data:
1. A novel brain-selective MAO inhibitor, Ladostigil can selectively reverse the behavioral and neurochemical effects induced by prenatal stress without affecting the behavior of controls. Antidepressant
2. A novel brain-selective MAO inhibitor, Ladostigil can selectively reverse the behavioral and neurochemical effects induced by prenatal stress without affecting the behavior of controls. Antidepressant.

InChI:InChI=1/2C16H20N2O2.C4H6O6/c2*1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2;5-1(3(7)8)2(6)4(9)10/h2*1,6,8,11,15,17H,5,7,9-10H2,2-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*15-;1-,2-/m111/s1

Upstream product

• 87-69-4 L-Tartaric acid 
• 209394-27-4 ladostigil 

Relevant articles and documents

Polymorphic forms of ladostigil tartrate

Provided are polymorphic forms of ladostigil tartrate and methods for preparation thereof.

Methods for isolating propargylated aminoindans

Disclosed is a process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan having the structure wherein R1 is H, hydroxyl, alkoxy or wherein Y is O or S; R2 and R3 is each, independently, C1-8 alkyl, C6-12 aryl, C6-12 aralkyl, each optionally halo substituted, or hydrogen; where the reaction mixture further comprises a solvent, a primary aminoindan having the structure wherein R1 is defined as above, and a tertiary aminoindan having the structure the process comprising d) adding an acid to the reaction mixture; e) crystallizing the mono-propargylated aminoindan under conditions suitable for the formation of a crystalline salt of the mono-propargylated aminoindan; and f) recovering the crystalline salt of the mono-propargylated aminoindan, wherein the process is performed without addition of an organic solvent. Also disclosed are the crystalline diastereomeric salts produced by the process and pharmaceutical compositions containing the salts.

Formulations of ladostigil tartrate

Disclosed are formulations of ladostigil tartrate, including pharmaceutical compositions, process for the manufacture, and use thereof.